vs
英特格（ENTG）与Revvity（RVTY）财务数据对比。点击上方公司名可切换其他公司
英特格的季度营收约是Revvity的1.1倍（$823.9M vs $772.1M），Revvity净利率更高（12.7% vs 6.0%，领先6.7%），Revvity同比增速更快（5.9% vs -3.1%），Revvity自由现金流更多（$161.8M vs $134.0M），过去两年Revvity的营收复合增速更高（9.0% vs 3.4%）
英特格是面向半导体及其他高科技行业的材料供应商，全球员工约8000人，总部位于美国马萨诸塞州比勒里卡。公司在全球多国及地区布局生产、客户服务与研发设施，覆盖美国、加拿大、中国、德国、以色列、日本、马来西亚、新加坡、韩国、中国台湾等地。
Revvity是一家美国生命科学与诊断领域企业，主要服务制药、生物技术行业客户，重点围绕细胞治疗、基因治疗等前沿技术领域提供相关产品与解决方案，其前身为业务布局多元的老牌企业珀金埃尔默。
ENTG vs RVTY — 直观对比
营收规模更大
ENTG
是对方的1.1倍
$772.1M
营收增速更快
RVTY
高出8.9%
-3.1%
净利率更高
RVTY
高出6.7%
6.0%
自由现金流更多
RVTY
多$27.8M
$134.0M
两年增速更快
RVTY
近两年复合增速
3.4%
损益表 — Q4 FY2025 vs Q4 FY2025
| 指标 | | |
|---|---|---|
| 营收 | $823.9M | $772.1M |
| 净利润 | $49.4M | $98.4M |
| 毛利率 | 43.8% | — |
| 营业利润率 | 12.7% | 14.5% |
| 净利率 | 6.0% | 12.7% |
| 营收同比 | -3.1% | 5.9% |
| 净利润同比 | -51.7% | 3.9% |
| 每股收益（稀释后） | $0.33 | $0.86 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收ENTGRVTY
| Q4 25 | $823.9M | $772.1M | ||
| Q3 25 | $807.1M | $698.9M | ||
| Q2 25 | $792.4M | $720.3M | ||
| Q1 25 | $773.2M | $664.8M | ||
| Q4 24 | $849.8M | $729.4M | ||
| Q3 24 | $807.7M | $684.0M | ||
| Q2 24 | $812.7M | $691.7M | ||
| Q1 24 | $771.0M | $649.9M |
净利润ENTGRVTY
| Q4 25 | $49.4M | $98.4M | ||
| Q3 25 | $70.5M | $46.7M | ||
| Q2 25 | $52.8M | $53.9M | ||
| Q1 25 | $62.9M | $42.2M | ||
| Q4 24 | $102.2M | $94.6M | ||
| Q3 24 | $77.6M | $94.4M | ||
| Q2 24 | $67.7M | $55.4M | ||
| Q1 24 | $45.3M | $26.0M |
毛利率ENTGRVTY
| Q4 25 | 43.8% | — | ||
| Q3 25 | 43.5% | 53.6% | ||
| Q2 25 | 44.4% | 54.5% | ||
| Q1 25 | 46.1% | 56.5% | ||
| Q4 24 | 45.6% | — | ||
| Q3 24 | 46.0% | 56.3% | ||
| Q2 24 | 46.2% | 55.7% | ||
| Q1 24 | 45.6% | 54.6% |
营业利润率ENTGRVTY
| Q4 25 | 12.7% | 14.5% | ||
| Q3 25 | 15.2% | 11.7% | ||
| Q2 25 | 13.4% | 12.6% | ||
| Q1 25 | 15.8% | 10.9% | ||
| Q4 24 | 17.6% | 16.3% | ||
| Q3 24 | 16.9% | 14.3% | ||
| Q2 24 | 16.0% | 12.4% | ||
| Q1 24 | 15.3% | 6.8% |
净利率ENTGRVTY
| Q4 25 | 6.0% | 12.7% | ||
| Q3 25 | 8.7% | 6.7% | ||
| Q2 25 | 6.7% | 7.5% | ||
| Q1 25 | 8.1% | 6.4% | ||
| Q4 24 | 12.0% | 13.0% | ||
| Q3 24 | 9.6% | 13.8% | ||
| Q2 24 | 8.3% | 8.0% | ||
| Q1 24 | 5.9% | 4.0% |
每股收益（稀释后）ENTGRVTY
| Q4 25 | $0.33 | $0.86 | ||
| Q3 25 | $0.46 | $0.40 | ||
| Q2 25 | $0.35 | $0.46 | ||
| Q1 25 | $0.41 | $0.35 | ||
| Q4 24 | $0.67 | $0.77 | ||
| Q3 24 | $0.51 | $0.77 | ||
| Q2 24 | $0.45 | $0.45 | ||
| Q1 24 | $0.30 | $0.21 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $360.4M | $919.9M |
| 总债务越低越好 | $3.7B | — |
| 股东权益账面价值 | $4.0B | $7.3B |
| 总资产 | $8.4B | $12.2B |
| 负债/权益比越低杠杆越低 | 0.94× | — |
8季度趋势，按日历期对齐
现金及短期投资ENTGRVTY
| Q4 25 | $360.4M | $919.9M | ||
| Q3 25 | $399.8M | $931.4M | ||
| Q2 25 | $376.8M | $991.8M | ||
| Q1 25 | $340.9M | $1.1B | ||
| Q4 24 | $329.2M | $1.2B | ||
| Q3 24 | $432.1M | $1.2B | ||
| Q2 24 | $320.0M | $2.0B | ||
| Q1 24 | $340.7M | $1.7B |
总债务ENTGRVTY
| Q4 25 | $3.7B | — | ||
| Q3 25 | $3.8B | — | ||
| Q2 25 | $4.0B | — | ||
| Q1 25 | $4.0B | — | ||
| Q4 24 | $4.0B | — | ||
| Q3 24 | $4.1B | — | ||
| Q2 24 | $4.1B | — | ||
| Q1 24 | $4.2B | — |
股东权益ENTGRVTY
| Q4 25 | $4.0B | $7.3B | ||
| Q3 25 | $3.9B | $7.4B | ||
| Q2 25 | $3.8B | $7.6B | ||
| Q1 25 | $3.7B | $7.6B | ||
| Q4 24 | $3.7B | $7.7B | ||
| Q3 24 | $3.6B | $7.9B | ||
| Q2 24 | $3.5B | $7.9B | ||
| Q1 24 | $3.4B | $7.8B |
总资产ENTGRVTY
| Q4 25 | $8.4B | $12.2B | ||
| Q3 25 | $8.4B | $12.1B | ||
| Q2 25 | $8.4B | $12.4B | ||
| Q1 25 | $8.4B | $12.4B | ||
| Q4 24 | $8.4B | $12.4B | ||
| Q3 24 | $8.5B | $12.8B | ||
| Q2 24 | $8.3B | $13.4B | ||
| Q1 24 | $8.4B | $13.4B |
负债/权益比ENTGRVTY
| Q4 25 | 0.94× | — | ||
| Q3 25 | 0.99× | — | ||
| Q2 25 | 1.05× | — | ||
| Q1 25 | 1.06× | — | ||
| Q4 24 | 1.08× | — | ||
| Q3 24 | 1.15× | — | ||
| Q2 24 | 1.18× | — | ||
| Q1 24 | 1.22× | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $192.0M | $182.0M |
| 自由现金流经营现金流 - 资本支出 | $134.0M | $161.8M |
| 自由现金流率自由现金流/营收 | 16.3% | 21.0% |
| 资本支出强度资本支出/营收 | 7.0% | 2.6% |
| 现金转化率经营现金流/净利润 | 3.89× | 1.85× |
| 过去12个月自由现金流最近4个季度 | $396.2M | $509.4M |
8季度趋势，按日历期对齐
经营现金流ENTGRVTY
| Q4 25 | $192.0M | $182.0M | ||
| Q3 25 | $249.5M | $138.5M | ||
| Q2 25 | $113.5M | $134.3M | ||
| Q1 25 | $140.4M | $128.2M | ||
| Q4 24 | $176.1M | $174.2M | ||
| Q3 24 | $197.2M | $147.9M | ||
| Q2 24 | $111.2M | $158.6M | ||
| Q1 24 | $147.2M | $147.6M |
自由现金流ENTGRVTY
| Q4 25 | $134.0M | $161.8M | ||
| Q3 25 | $182.8M | $120.0M | ||
| Q2 25 | $47.0M | $115.5M | ||
| Q1 25 | $32.4M | $112.2M | ||
| Q4 24 | $68.6M | $149.8M | ||
| Q3 24 | $115.0M | $125.6M | ||
| Q2 24 | $51.9M | $136.6M | ||
| Q1 24 | $80.6M | $129.7M |
自由现金流率ENTGRVTY
| Q4 25 | 16.3% | 21.0% | ||
| Q3 25 | 22.6% | 17.2% | ||
| Q2 25 | 5.9% | 16.0% | ||
| Q1 25 | 4.2% | 16.9% | ||
| Q4 24 | 8.1% | 20.5% | ||
| Q3 24 | 14.2% | 18.4% | ||
| Q2 24 | 6.4% | 19.7% | ||
| Q1 24 | 10.4% | 20.0% |
资本支出强度ENTGRVTY
| Q4 25 | 7.0% | 2.6% | ||
| Q3 25 | 8.3% | 2.6% | ||
| Q2 25 | 8.4% | 2.6% | ||
| Q1 25 | 14.0% | 2.4% | ||
| Q4 24 | 12.7% | 3.4% | ||
| Q3 24 | 10.2% | 3.3% | ||
| Q2 24 | 7.3% | 3.2% | ||
| Q1 24 | 8.6% | 2.7% |
现金转化率ENTGRVTY
| Q4 25 | 3.89× | 1.85× | ||
| Q3 25 | 3.54× | 2.97× | ||
| Q2 25 | 2.15× | 2.49× | ||
| Q1 25 | 2.23× | 3.03× | ||
| Q4 24 | 1.72× | 1.84× | ||
| Q3 24 | 2.54× | 1.57× | ||
| Q2 24 | 1.64× | 2.87× | ||
| Q1 24 | 3.25× | 5.67× |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
ENTG
| Fabs | $516.3M | 63% |
| Equipment And Engineering | $121.8M | 15% |
| Chemical And Materials | $83.8M | 10% |
| Other | $61.7M | 7% |
| Non Semi | $40.3M | 5% |
RVTY
| Immunodiagnostics | $240.8M | 31% |
| Life Sciences | $191.4M | 25% |
| Reproductive Health | $149.3M | 19% |
| Segment Operating Income | $132.0M | 17% |
| Software | $62.3M | 8% |
